{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:00:30Z","timestamp":1795129230956,"version":"4.10.3"},"reference-count":190,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.amjms.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:39:59Z","timestamp":1602146399000},"page":"176-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":232,"title":["IgA Nephropathy: An Interesting Autoimmune Kidney Disease"],"prefix":"10.1016","volume":"361","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7564-6362","authenticated-orcid":false,"given":"Arun","family":"Rajasekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2020.10.003_bib0001","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0002","first-page":"709","article-title":"The commonest glomerulonephritis in the world: igA nephropathy","volume":"64","author":"D\u2019Amico","year":"1987","journal-title":"Q J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0003","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D'Amico","year":"2004","journal-title":"Seminars in nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0005","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.2005020134","article-title":"IgA nephropathy","volume":"16","author":"Barratt","year":"2005","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0006","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0007","series-title":"Heptinstall's Pathology of the Kidney","first-page":"423","article-title":"IgA nephropathy and Henoch-Schoenlein purpura nephritis","author":"Haas","year":"2007"},{"key":"10.1016\/j.amjms.2020.10.003_bib0008","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1523-1755.2004.00834.x","article-title":"Epidemiologic data of primary glomerular diseases in western","volume":"66","author":"Simon","year":"2004","journal-title":"France Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0009","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMra020109","article-title":"IgA nephropathy","volume":"347","author":"Donadio","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0010","doi-asserted-by":"crossref","unstructured":"Utsunomiya Y, Koda T, Kado T, et\u00a0al. Incidence of pediatric IgA nephropathy. Pediatr Nephrol 2003;18(6):511\u20135.","DOI":"10.1007\/s00467-003-1127-z"},{"key":"10.1016\/j.amjms.2020.10.003_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10157-015-1129-8","article-title":"Epidemiological survey and clinical investigation of pediatric IgA nephropathy","volume":"20","author":"Shibano","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0012","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ki.2013.329","article-title":"The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation","volume":"85","author":"McQuarrie","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0013","doi-asserted-by":"crossref","first-page":"c337","DOI":"10.1159\/000319594","article-title":"Global evolutionary trend of the prevalence of primary glomerulonephritis over the past three decades","volume":"116","author":"Woo","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.amjms.2020.10.003_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-007-0010-9","article-title":"Chronic kidney disease perspectives in Japan and the importance of urinalysis screening","volume":"12","author":"Yamagata","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0015","first-page":"853","article-title":"Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994","volume":"9","author":"Wyatt","year":"1998","journal-title":"Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0016","first-page":"163","article-title":"IgA nephropathy in the triethnic population of New Mexico","volume":"72","author":"Fischer","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00005792-198501000-00004","article-title":"Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients","volume":"64","author":"D'Amico","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00005792-199403000-00002","article-title":"IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature","volume":"73","author":"Ibels","year":"1994","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0002-9343(90)90300-3","article-title":"A retrospective analysis of the natural history of primary IgA nephropathy worldwide","volume":"89","author":"Schena","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-3476(95)70027-7","article-title":"IgA nephropathy: long-term prognosis for pediatric patients","volume":"127","author":"Wyatt","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.amjms.2020.10.003_bib0021","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfg207","article-title":"A tricontinental view of IgA nephropathy","volume":"18","author":"Geddes","year":"2003","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0022","doi-asserted-by":"crossref","first-page":"c149","DOI":"10.1159\/000092912","article-title":"Clinicopathological characteristics and outcome of adult patients with hematuria and\/or proteinuria found during routine examination","volume":"103","author":"Shen","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.amjms.2020.10.003_bib0023","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/jcp.46.7.607","article-title":"Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death","volume":"46","author":"Varis","year":"1993","journal-title":"Journal of clinical pathology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0024","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0026","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0027","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0272-6386(88)80022-2","article-title":"The immunohistology of IgA nephropathy","volume":"12","author":"Jennette","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0028","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ndt\/gfn563","article-title":"Mesangial C4d deposition: a new prognostic factor in IgA nephropathy","volume":"24","author":"Espinosa","year":"2009","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0029","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00844284","article-title":"Immunohistochemical study of the membrane attack complex of complement in IgA nephropathy","volume":"413","author":"Miyamoto","year":"1988","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0030","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0031","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1172\/JCI109998","article-title":"Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus","volume":"66","author":"Conley","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjms.2020.10.003_bib0032","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2249.1995.tb03724.x","article-title":"Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy","volume":"100","author":"Allen","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0033","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0590031077.x","article-title":"Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy","volume":"59","author":"Hiki","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0034","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0036","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNH.0b013e32835fe65c","article-title":"Oxford classification of immunoglobulin A nephropathy: an update","volume":"22","author":"Roberts","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjms.2020.10.003_bib0037","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0038","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0039","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.V82199","article-title":"Predicting renal outcome in IgA nephropathy","volume":"8","author":"Radford","year":"1997","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0041","series-title":"Comprehensive Clinical Nephrology","first-page":"275","author":"Feehally","year":"2019"},{"key":"10.1016\/j.amjms.2020.10.003_bib0042","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2215\/CJN.04820511","article-title":"Clinical features and outcomes of IgA nephropathy with nephrotic syndrome","volume":"7","author":"Kim","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0043","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/ajcp\/86.6.716","article-title":"An overlapping syndrome of IgA nephropathy and lipoid nephrosis","volume":"86","author":"Lai","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0044","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2215\/CJN.11951113","article-title":"IgA nephropathy with minimal change disease","volume":"9","author":"Herlitz","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00005792-198411000-00005","article-title":"Crescentic IgA nephropathy","volume":"63","author":"Abuelo","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0046","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2215\/CJN.02670706","article-title":"Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy","volume":"2","author":"Gutierrez","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0047","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0272-6386(88)80028-3","article-title":"Is Henoch-Schonlein purpura the systemic form of IgA nephropathy?","volume":"12","author":"Waldo","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0048","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000102455","article-title":"IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells","volume":"157","author":"Novak","year":"2007","journal-title":"Contributions to nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0049","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ekir.2019.08.015","article-title":"Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis","volume":"4","author":"Suzuki","year":"2019","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1523-1755.2001.060003969.x","article-title":"Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients","volume":"60","author":"Allen","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0051","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","article-title":"Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins","volume":"360","author":"Gardner-Medwin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0052","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/art.1780400513","article-title":"Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome","volume":"40","author":"Blanco","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2020.10.003_bib0053","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjd.12946","article-title":"Incidence of IgA vasculitis in the adult Slovenian population","volume":"171","author":"Hocevar","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0054","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/BOR.0b013e32835d8e2a","article-title":"Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein): current state of knowledge","volume":"25","author":"Piram","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0055","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/adc.2009.167874","article-title":"Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study","volume":"95","author":"Jauhola","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.amjms.2020.10.003_bib0056","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00431-017-2990-0","article-title":"Blistering eruptions in Henoch-Schonlein syndrome: more common than assumed","volume":"177","author":"Peeters","year":"2018","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.amjms.2020.10.003_bib0057","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00431-009-1101-2","article-title":"Clinical practice: diagnosis and management of Henoch-Schonlein purpura","volume":"169","author":"McCarthy","year":"2010","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.amjms.2020.10.003_bib0058","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.1780330808","article-title":"The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis","volume":"33","author":"Calabrese","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2020.10.003_bib0059","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/art.1780330809","article-title":"The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura","volume":"33","author":"Mills","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2020.10.003_bib0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOP.0b013e3282f4308b","article-title":"IgA nephropathy and Henoch-Schonlein purpura nephritis","volume":"20","author":"Sanders","year":"2008","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.amjms.2020.10.003_bib0061","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2014.126","article-title":"Henoch-Schonlein purpura nephritis in children","volume":"10","author":"Davin","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0062","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2215\/CJN.06710810","article-title":"Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy","volume":"6","author":"Davin","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0063","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","article-title":"The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study","volume":"360","author":"Ronkainen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0064","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","article-title":"Predictors of outcome in Henoch-Schonlein nephritis in children and adults","volume":"47","author":"Coppo","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0065","first-page":"2277","article-title":"Long-term prognosis of Henoch-Schonlein nephritis in adults and children","volume":"12","author":"Coppo","year":"1997","journal-title":"Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schonlein purpura Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0066","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.autrev.2014.01.031","article-title":"The diagnosis and classification of Henoch-Schonlein purpura: an updated review","volume":"13","author":"Yang","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.amjms.2020.10.003_bib0067","first-page":"309","article-title":"Recurrent mesangial IgA nephritis following renal transplantation","volume":"9","author":"Odum","year":"1994","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0068","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12882-018-1135-7","article-title":"Recurrent glomerulonephritis following renal transplantation and impact on graft survival","volume":"19","author":"Jiang","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0069","first-page":"241","article-title":"Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation","volume":"33","author":"Silva","year":"1982","journal-title":"Transplantation"},{"key":"10.1016\/j.amjms.2020.10.003_bib0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.coi.2008.04.002","article-title":"Evolution, development, mechanism and function of IgA in the gut","volume":"20","author":"Fagarasan","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0071","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/mi.2011.39","article-title":"Structure and function relationships in IgA","volume":"4","author":"Woof","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0072","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/19490976.2014.969977","article-title":"Re-thinking the functions of IgA(+) plasma cells","volume":"5","author":"Gommerman","year":"2014","journal-title":"Gut Microbes"},{"key":"10.1016\/j.amjms.2020.10.003_bib0073","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.1877","article-title":"The function of immunoglobulin A in immunity","volume":"208","author":"Woof","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0074","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2008.08.001","article-title":"How host-bacterial interactions lead to IgA synthesis in the gut","volume":"29","author":"Suzuki","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0075","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjms.2020.10.003_bib0076","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1016\/S0021-9258(19)42101-7","article-title":"Structure of the carbohydrate units of IgA1 immunoglobulin. II. Structure of the O-glycosidically linked oligosaccharide units","volume":"249","author":"Baenziger","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjms.2020.10.003_bib0077","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1074\/jbc.273.4.2260","article-title":"The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcalpha receptor interactions","volume":"273","author":"Mattu","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjms.2020.10.003_bib0078","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1093\/ndt\/gfp441","article-title":"Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time?","volume":"24","author":"Barratt","year":"2009","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0079","first-page":"50","article-title":"Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy","volume":"157","author":"Buren","year":"2007","journal-title":"Contributions to nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0080","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0081","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ki.1994.110","article-title":"Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy","volume":"45","author":"Harper","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0082","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jcp.49.1.38","article-title":"Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA","volume":"49","author":"Harper","year":"1996","journal-title":"Journal of clinical pathology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0083","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0084","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy","volume":"19","author":"Gharavi","year":"2008","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0085","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"Suzuki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjms.2020.10.003_bib0086","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/ki.2010.314","article-title":"Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy","volume":"78","author":"Vuong","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0087","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0088","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0022-2143(99)90008-2","article-title":"Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy?","volume":"133","author":"Leung","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0089","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF01715838","article-title":"The mesangium and glomerulonephritis","volume":"60","author":"Sterzel","year":"1982","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.amjms.2020.10.003_bib0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.194.4.417","article-title":"Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy","volume":"194","author":"Moura","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0091","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0092","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrneph.2012.58","article-title":"Pathogenesis of IgA nephropathy","volume":"8","author":"Lai","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0093","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10157-012-0660-0","article-title":"Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy","volume":"17","author":"Wada","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0094","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/ndt\/gfq812","article-title":"Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort","volume":"26","author":"Bellur","year":"2011","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0095","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1","volume":"30","author":"Rizk","year":"2019","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0096","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0140-6736(79)92505-4","article-title":"IgA immune complexes in Henoch-Schonlein purpura","volume":"2","author":"Levinsky","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0097","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.kint.2018.02.030","article-title":"Secondary IgA nephropathy","volume":"94","author":"Saha","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0098","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semnephrol.2007.10.004","article-title":"Secondary IgA nephropathy","volume":"28","author":"Pouria","year":"2008","journal-title":"Seminars in nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0099","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1097\/TXD.0000000000000708","article-title":"Renal Outcomes in Patients With IgA Nephropathy Undergoing Liver Transplant: a Retrospective Cohort Study","volume":"3","author":"Hommos","year":"2017","journal-title":"Transplant Direct"},{"key":"10.1016\/j.amjms.2020.10.003_bib0100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfv221","article-title":"Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy","volume":"30","author":"Yasutake","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.amjms.2020.10.003_bib0101","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis","volume":"93","author":"Suzuki","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0102","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1093\/ndt\/gfz152","article-title":"Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy","volume":"35","author":"Cassol","year":"2019","journal-title":"Nephrology, dialysis, transplantation\u202f: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0103","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ndt\/17.4.542","article-title":"Controversies concerning the importance of genetic polymorphism in IgA nephropathy","volume":"17","author":"Frimat","year":"2002","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000381738","article-title":"The Genetics of IgA Nephropathy: an Overview from Western Countries","volume":"1","author":"Feehally","year":"2015","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0106","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0107","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1038\/ncomms8270","article-title":"Identification of new susceptibility loci for IgA nephropathy in Han Chinese","volume":"6","author":"Li","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.amjms.2020.10.003_bib0108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006609","article-title":"GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway","volume":"13","author":"Kiryluk","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0109","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.2016091043","article-title":"Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1","volume":"28","author":"Gale","year":"2017","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0110","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1681\/ASN.2010010076","article-title":"HLA has strongest association with IgA nephropathy in genome-wide analysis","volume":"21","author":"Feehally","year":"2010","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0112","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1172\/JCI119596","article-title":"Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients","volume":"100","author":"Pei","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjms.2020.10.003_bib0113","first-page":"152","article-title":"Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy","volume":"22","author":"Pirulli","year":"2009","journal-title":"J Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0114","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","article-title":"Regression of IgA nephropathy: a repeat biopsy study","volume":"39","author":"Hotta","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0115","first-page":"160","article-title":"Repeat renal biopsy in children with IgA nephropathy","volume":"33","author":"Yoshikawa","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0116","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1681\/ASN.2010040355","article-title":"Predicting the risk for dialysis or death in IgA nephropathy","volume":"22","author":"Berthoux","year":"2011","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0117","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2001.27689","article-title":"Predicting progression in IgA nephropathy","volume":"38","author":"Bartosik","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0118","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/ndt\/17.7.1197","article-title":"Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy","volume":"17","author":"Donadio","year":"2002","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0119","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0120","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0121","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0122","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0123","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s10157-012-0613-7","article-title":"Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters","volume":"16","author":"Kataoka","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0124","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1440-1797.2007.00898.x","article-title":"Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China","volume":"13","author":"Lv","year":"2008","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0125","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.2215\/CJN.01170211","article-title":"The use of the Oxford classification of IgA nephropathy to predict renal survival","volume":"6","author":"Alamartine","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0126","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA Nephropathy: a Nationwide Population-Based Cohort Study","volume":"30","author":"Jarrick","year":"2019","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/kisup.2012.23","article-title":"KDIGO clinical practice guidelines for glomerulonephritis - Chapter 10: immunoglobulin A nephropathy","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0129","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0130","series-title":"European Medicines Agency's Committee for Medicinal Products For Human Use (CHMP): Restriction of Combined Use of Medicines Affecting the Renin-Angiotensin System (RAS)","year":"2014"},{"key":"10.1016\/j.amjms.2020.10.003_bib0131","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1067\/mcp.2000.105330","article-title":"Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy","volume":"67","author":"Buemi","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjms.2020.10.003_bib0132","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.jrn.2014.01.016","article-title":"The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial","volume":"24","author":"Kittiskulnam","year":"2014","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.amjms.2020.10.003_bib0133","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ekir.2017.01.007","article-title":"The Renal Pathology of Obesity","volume":"2","author":"Tsuboi","year":"2017","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0134","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.ajkd.2010.02.351","article-title":"Cigarette smoking and progression of IgA nephropathy","volume":"56","author":"Yamamoto","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0135","doi-asserted-by":"crossref","unstructured":"Navaneethan S.D., Shao J., Buysse J., et\u00a0al. Effects of Treatment of Metabolic Acidosis in CKD A Systematic Review and Meta-Analysis 2019;14:1011\u201320.","DOI":"10.2215\/CJN.13091118"},{"key":"10.1016\/j.amjms.2020.10.003_bib0136","doi-asserted-by":"crossref","first-page":"c30","DOI":"10.1159\/000341929","article-title":"Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: a meta-analysis of randomized controlled trials","volume":"121","author":"Chou","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.amjms.2020.10.003_bib0137","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0138","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0139","first-page":"432","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: the TESTING Randomized","volume":"318","author":"Lv","year":"2017","journal-title":"Clinical Trial Jama"},{"key":"10.1016\/j.amjms.2020.10.003_bib0140","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA Nephropathy: a Retrospective Analysis from the VALIGA Study","volume":"26","author":"Tesar","year":"2015","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0141","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0142","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1681\/ASN.2012101017","article-title":"Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study","volume":"24","author":"Lv","year":"2013","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0143","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semnephrol.2004.01.006","article-title":"Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy","volume":"24","author":"Tumlin","year":"2004","journal-title":"Seminars in nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0144","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12882-017-0647-x","article-title":"Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis","volume":"18","author":"Du","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0146","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0147","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2020.10.003_bib0148","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0149","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0150","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0151","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.semnephrol.2007.10.008","article-title":"Potential Immunopathogenic Role of the Mucosa\u2013Bone Marrow Axis in IgA Nephropathy: insights From Animal Models","volume":"28","author":"Suzuki","year":"2008","journal-title":"Seminars in nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0152","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10157-013-0779-7","article-title":"Nationwide survey on current treatments for IgA nephropathy in Japan","volume":"17","author":"Matsuzaki","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0153","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.amjms.2020.10.003_bib0154","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40620-015-0247-4","article-title":"The role of tonsillectomy in IgA nephropathy","volume":"29","author":"Feriozzi","year":"2016","journal-title":"J Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.amjms.2020.10.003_bib0156","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2017.05.021","article-title":"Mucosal corticosteroid therapy of IgA nephropathy","volume":"92","author":"Floege","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0157","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2020.10.003_bib0158","unstructured":"Efficacy and safety of nefecon in patients with primary IgA (Immunoglobulin A) nephropathy. 2018. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT03643965. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0159","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0160","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","article-title":"Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties","volume":"95","author":"Goldman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2020.10.003_bib0161","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: a Randomized Controlled Trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0162","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12882-019-1488-6","article-title":"Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study","volume":"20","author":"Y-z","year":"2019","journal-title":"BMC Nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0163","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1681\/ASN.2009101025","article-title":"Melanocortin 1 receptor agonists reduce proteinuria","volume":"21","author":"Lindskog","year":"2010","journal-title":"Journal of the American Society of Nephrology : JASN"},{"key":"10.1016\/j.amjms.2020.10.003_bib0164","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ackd.2013.09.004","article-title":"Leveraging melanocortin pathways to treat glomerular diseases","volume":"21","author":"Gong","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.amjms.2020.10.003_bib0165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ekir.2019.10.007","article-title":"An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression","volume":"5","author":"Zand","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.amjms.2020.10.003_bib0166","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2020.10.003_bib0167","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for Reduction of Proteinuria in IgA Nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0168","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1749-6632.2011.06266.x","article-title":"Regulation of mucosal IgA responses: lessons from primary immunodeficiencies","volume":"1238","author":"Cerutti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.amjms.2020.10.003_bib0169","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaa140.MO039","article-title":"MO039 The 24-Week Interim Analysis Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria","volume":"35","author":"Barratt","year":"2020","journal-title":"Nephrology Dialysis Transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1016\/j.amjms.2020.10.003_bib0170","unstructured":"Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration. 2013. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02062684. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0171","unstructured":"Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy. 2014. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02112838. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0172","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.ekir.2019.05.431","article-title":"Spleen tyrosine kinase (SYK) inhibition in IgA Nephropathy: a gobal, phase II, randomized placebo-controlled trial of fostamatinib","volume":"4","author":"Tam Wk","year":"2019","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0173","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10875-013-9970-6","article-title":"C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy","volume":"34","author":"Liu","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0174","unstructured":"Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade. 2015. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02384317. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ndt\/gfx129.TO012","article-title":"TO012C5A receptor inhibitor Avacopan in IgA Nephropathy study","volume":"32","author":"Bruchfeld","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.amjms.2020.10.003_bib0176","unstructured":"A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN). Available at:https:\/\/ClinicalTrials.gov\/show\/NCT03841448. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0177","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy","author":"Lafayette","year":"2020","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0178","unstructured":"Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT03608033. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0179","unstructured":"A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT03762850. Accessed December 8, 2020."},{"key":"10.1016\/j.amjms.2020.10.003_bib0180","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ekir.2019.08.007","article-title":"Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)","volume":"4","author":"Barratt","year":"2019","journal-title":"Kidney international reports"},{"key":"10.1016\/j.amjms.2020.10.003_bib0181","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000341914","article-title":"The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schonlein purpura nephritis","volume":"36","author":"Ren","year":"2012","journal-title":"American journal of nephrology"},{"key":"10.1016\/j.amjms.2020.10.003_bib0182","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/kisup.2012.24","article-title":"Chapter 11: henoch-Schonlein purpura nephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.amjms.2020.10.003_bib0183","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1046\/j.1523-1755.2001.00006.x","article-title":"Kidney transplantation in patients with IgA mesangial glomerulonephritis","volume":"60","author":"Ponticelli","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.10.003_bib0184","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1111\/j.1399-0012.2011.01424.x","article-title":"Pre-transplant course and risk of kidney transplant failure in IgA nephropathy patients","volume":"25","author":"Bjorneklett","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.amjms.2020.10.003_bib0185","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181705ad4","article-title":"Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy","volume":"85","author":"Berthoux","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.amjms.2020.10.003_bib0186","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1600-6143.2011.03667.x","article-title":"Steroids and recurrent IgA nephropathy after kidney transplantation","volume":"11","author":"Clayton","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.amjms.2020.10.003_bib0187","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.2215\/CJN.00520111","article-title":"Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis","volume":"6","author":"Kanaan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.10.003_bib0188","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/TP.0b013e31822e0bcf","article-title":"Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy","volume":"92","author":"Thervet","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.amjms.2020.10.003_bib0189","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/j.1600-6143.2007.01928.x","article-title":"Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence","volume":"7","author":"Hiremath","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.amjms.2020.10.003_bib0190","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000377684","article-title":"Clinicopathologic Features of IgA-Dominant Infection-Associated Glomerulonephritis: a Pooled Analysis of 78 Cases","volume":"41","author":"Bu","year":"2015","journal-title":"American Journal of Nephrology"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920304353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920304353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:38:47Z","timestamp":1757702327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920304353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":190,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0002962920304353"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.10.003","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgA Nephropathy: An Interesting Autoimmune Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}